CClinicalTrials.gg
CompletedNCT05351372Updated May 4, 2022

Validation of X-ray Protocols in Cleft Children

An interventional study of Ultra-low dose protocol and Standard dose protocol in Evaluate CBCT Protocols in Subjective Image Quality, sponsored by Karolinska Institutet. Completed at 1 site in Sweden. Per ClinicalTrials.gov, last updated 2022-05-04.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 5 years 10 months after the study started (first participant enrolled May 2016, registered Apr 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Sex
All
01

Study summary

Children born with an alveolar cleft receive bone grafts for improved function and aesthetics. The cleft area is radiologically examined before and post bone graft. Optimizing x-ray examination protocols is essential to protect these patients from possible delayed radiation injury later in life. This study investigates whether image quality of cone-beam computed tomography (CBCT) exposed with an ultra-low dose (ULD) protocol is comparable to the clinical default protocol, the standard dose (SD) protocol, in visualizing details of importance in bone grafting of alveolar clefts.

Methods In this randomized controlled study, 72 patients with uni- or bilateral alveolar clefts between 9-19 years (mean age 9.5) were randomized 1:1 with either a ULD or an SD CBCT examination protocol. The CBCT scans were conducted with Planmeca ProMax Mid with an 8x5cm field of view. Two experienced radiologists blindly evaluated the images and visibility of cortical bone border, trabecular bone, tooth anatomy, root development, periodontal space, and cleft width. The visibility was categorized as unacceptable, acceptable, or excellent.

Read the detailed description

Radiographic imaging is an integral part of diagnostics, therapy planning and post-surgery assessment. Cone beam computed tomography (CBCT) was introduced in the late 90s and is now widely accepted. The technique utilizes a cone shaped X-ray beam to directly create a volumetric data, with predefined fields of view (FOV). CBCT provides 3D information with excellent spatial resolution, enabling assessment of anatomical variations and pathological changes in bone.

Cleft lip and palate disorder are among the most common birth defects, with the reported incidence in the Stockholm region of 1.7/1000 live births. The malformation can involve the lip, the alveolar process and the palate. When the alveolar process is involved CBCT can be indicated to assess the local anatomy prior to and after bone augmentation.

Minimizing the radiation dosage is especially important for children since the estimated risk for cancer formation or hereditable effects is approximately 3 times higher than for an adult aged 30.

Therefore the developments of low dose protocols within CBCT techniques are progressing rapidly. By applying more sensitive detector and a sophisticated image processing algorithm, the manufacturer Planmeca claimed that with Ultra Low Dose (ULD) protocol the effective patient dose may be reduced by up to 76%. A consequence of dramatically reduced exposure is the decreased signal-noise ratio, in other words reduced image quality, which results in increased diagnostic uncertainty of detailed structures. Since the accepted diagnostic image quality is highly associated with diagnostic tasks, clinical studies on evaluation new diagnostic feature are important.

HYPOTHESIS/RESEARCH QUESTION Will Promax 3D Mid CBCT with ULD normal dose protocol provide adequate information in order to assess necessary clinical questions in the region of the maxillary alveolar cleft compared to normal dose protocol?

METHODS Study design Randomized controlled trial examining the effect of two different Promax 3D Mid CBCT protocols, i.e. ULD normal dose setting versus normal dose setting, on image quality examining children with cleft involving the alveolar process.

Data source All patients with cleft involving the alveolar process, having treatment at Stockholm Craniofacial Centre Karolinska university hospital, being referred to Division of orofacial diagnostics and surgery - Image and functional odontology, Karolinska Institutet. Reason for referral CBCT examination to evaluate anatomy of the anterior maxilla prior to or after bone augmentation of the cleft located to the alveolar process.

Exposure/Intervention The exposure in the planned study is radiographic examination of children with cleft involving the alveolar process with CBCT Ultra Low Dose protocol compared with Normal dose protocol.

The study will be double blinded, nor will the patient nor the observers performing the evaluation of the images know the allocation. All observer assessment will be performed at one specific computer work station using the software program (Romexis Planmeca OY Helsinki Finland). The examinations will be executed by one of two possible nurses with extensive experience from handling CBCT devices. For the nurse the allocation cannot be concealed since the actual setting of the parameters has to be done manually. Therefore, a triple blinded design seems impossible. Since the same modality is used, Promax 3D Mid CBCT (Planmeca OY Helsinki Finland) for both protocols no evident risk exist that the patient or accompanying parent/guardian will work out the actual protocol in use.

In order to randomize the cases will be sectioned in groups of ten in a 1:1 assignment to either of the two protocols. The sequence for each group will be predetermined by lottery. Ten folded papers with equal size will be drawn by a person blindfolded without any knowledge of the study. The papers will be marked ULD for ULD normal dose protocol respectively NORMAL for normal dose protocol. The sequence for each group will be registered and provided up on the time for examination in a cover in the lab adjacent to the CBCT device. The idea with dividing cases and controls in groups, five of each resulting in a total of ten, is to ensure that the relation between the numbers of the two protocols is balanced.

The image conditions chosen for the Field of View (FOV) is 80mm in diameter and 50mm in height. The reason for not choosing a smaller, FOV i.e. 40 x 50 mm, decreasing the effective dose even further, is to provide information also on the contralateral side of the maxilla, a request from the surgeons giving important information needed during treatment planning. Normal clinical procedure using axial, coronal and sagital reconstructions of 1 mm thick slices will be used for the evaluation. Axial slices are according to standard in 3D imaging reconstructed parallel to the hard palate while paracoronal and parasagittal are perpendicular to the alveolar crest on the cleft side. All reconstructive work and imaging will be made in the software program Romexis (Planmeca OY Helsinki Finland). The examinations and reconstructions will be similar of those in a recent study from Finland in 2014.

Two dentomaxillofacial radiologists with profound knowledge and experience in assessing CBCT images will evaluate all radiographic 3D material. The 3D volumes will randomly be displayed using the same model of monitor (RadiForce MX191; EIZO, Hakusan, Japan), with a built-in digital imaging and communications in medicine setting. The radiographs will be evaluated under dimmed room light and a viewing distance of about 50 cm. The observers are allowed to adjust the window setting for light intensity and contrast according to their own preferences.

According to a three-point scale, the image quality will be assessed based on how well the observers can identify anatomical structures of interest prior to or post bone graft (unacceptable=1, acceptable=2, excellent=3). The landmarks of evaluation will be the cortical border of bone adjacent to the cleft, alveolar bone nearby the cleft, tooth anatomy of teeth adjacent to the cleft, root development, the periodontal space, and the width of the cleft. Possible motion artefacts presented in the CBCT images will be registered as minor or apparent. In case of a discrepancy between the two radiologists, the mean value of the observer's ratings is recorded.

02

Conditions studied

  • Evaluate CBCT Protocols in Subjective Image Quality
03

In context

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,113 studies on the registry; 267 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with cleft involving the alveolar process undergoing treatment at Stockholm Craniofacial Centre
  • Reason for referral is CBCT examination in order to evaluate anatomy of the anterior maxilla prior to or after bone augmentation of the cleft
  • Patient/parent has given informed consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • No informed consent is given. Those patients will be examined according to standard clinical procedures.
  • Patients with a medical history of disorder/syndrome/chronic disease that will affect both the examination and the outcome.
  • No CBCT examination of the cleft area.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    ULD protocol

    ultra-low dose protocol in cone-beam computed tomography with a field of view including the cleft area

    Radiation: Ultra-low dose protocol

  • Active comparator
    Standard dose protocol

    Standard dose protocol in cone-beam computed tomography with a field of view including the cleft area

    Radiation: Standard dose protocol

Interventions

  • RadiationUltra-low dose protocol
  • RadiationStandard dose protocol
06

What researchers measure

Primary outcomes

  1. Subjective image quality

    unacceptable=1, acceptable=2, excellent=3

    Time frame: 6 months

Secondary outcomes

  1. cortical border of bone adjacent to the cleft

    unacceptable=1, acceptable=2, excellent=3

    Time frame: 6 months

  2. alveolar bone nearby the cleft

    unacceptable=1, acceptable=2, excellent=3

    Time frame: 6 months

  3. tooth anatomy of teeth adjacent to the cleft

    unacceptable=1, acceptable=2, excellent=3

    Time frame: 6 months

  4. root development

    unacceptable=1, acceptable=2, excellent=3

    Time frame: 6 months

  5. periorontal space visibility

    unacceptable=1, acceptable=2, excellent=3

    Time frame: 6 months

  6. Width of the cleft

    unacceptable=1, acceptable=2, excellent=3

    Time frame: 6 months

07

Study locations

1 site
  • Karolinska Institutet
    Stockholm, 14154, Sweden
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05351372
Lead sponsor
Karolinska Institutet
Responsible party
Tobias Regnstrand (Resident i Dentomaxillofacial radiology, PhD student, Karolinska Institutet) — Principal investigator
First posted
Apr 28, 2022
Start date
May 31, 2016
Primary completion
May 18, 2017
Completion
May 18, 2017
Last update
May 4, 2022

Study contacts

Xie-qi Shi, PhD
principal investigator · University of Bergen

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion